Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA)

Sponsor
NYU Langone Health (Other)
Overall Status
Recruiting
CT.gov ID
NCT05615922
Collaborator
(none)
30
1
1
24
1.2

Study Details

Study Description

Brief Summary

The purpose of this study is to establish the feasibility of a program of remotely supervised transcranial direct current stimulation (RS-tDCS) paired with language skills practice for people living with the semantic or logopenic variants of primary progressive aphasia (PPA). There are currently no established standard-of-care treatments for PPA. This study will evaluate whether RS-tDCS combined with language skills practice is a feasible study design for individuals with PPA.

Condition or Disease Intervention/Treatment Phase
  • Device: Transcranial Direct Current Stimulation (tDCS)
  • Behavioral: Word-Naming Activity
Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA)
Actual Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
Nov 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Remotely Supervised tDCS and Word-Naming Practice

At each session, the tDCS device will deliver 2.0 mA electric current for 30 minutes over the left frontotemporal lobe with focus on the inferior frontal gyrus (IFG). Participants will receive 20 intervention sessions over the course of the interventional period (4 weeks) on weekdays (Monday-Friday). During the stimulation period, participants will engage in a picture-naming exercise as guided by the study tDCS clinicians.

Device: Transcranial Direct Current Stimulation (tDCS)
tDCS is noninvasive brain stimulation device that modulates brain activity by delivering a low-intensity electrical current (2.0 mA) through scalp sponge electrodes. The device is preprogrammed to ramp up to 2.0 mA (for 30 seconds), provide constant current throughout session (29 minutes), and then ramp down (for 30 seconds) at the end.
Other Names:
  • Soterix Medical mini-CT Model 1601-LTE Stimulator
  • Behavioral: Word-Naming Activity
    During each tDCS session, the tDCS clinician will guide the participant in a word-naming exercise. Participants will be presented with photos of target items and prompted to verbally produce the names of the pictures.

    Outcome Measures

    Primary Outcome Measures

    1. Percentage of Participants who Complete 16 out of 20 Study Visits [Week 4]

      Measure of feasibility.

    Secondary Outcome Measures

    1. Number of Trained Language Probes at Treatment End [Week 4]

    2. Number of Untrained Language Probes at Treatment End [Week 4]

    3. Change in Aphasia Communication Outcome Measure (ACOM) Score [Baseline, Month 6]

      Measurement of patient-reported communicative functioning in aphasia. Scores are presented as T-Scores that range from 0 to 100; higher T-scores indicate greater functional communication skills.

    4. Change in Stroke and Aphasia Quality of Life-39 Item (SAQOL-39) Score [Baseline, Month 6]

      39-item assessment of quality of life among individuals with aphasia. Items are ranked on a Likert scale ranging from 1 (Couldn't do it at all) to 5 (No trouble at all). The total score is the average score of all items and ranges from 1 to 5; higher scores indicate greater quality of life.

    5. Change in Patient-Reported Outcomes Measurement Information System (PROMIS) - Social Roles and Activities Score [Baseline, Month 6]

      35-item measurement of the perceived ability to perform one's usual social roles and activities. Each item is rated on a Likert scale ranging from 5 (never) to 1 (always). The raw score is the sum of responses and is converted to a T-score that has a population mean score of 50 with a standard deviation of 10; higher scores indicate greater ability to perform social roles and activities.

    6. Change in Patient-Reported Outcomes Measurement Information System (PROMIS) - Global Health Score [Baseline, Month 6]

      10-item measurement of symptoms, functioning, and healthcare-related quality of life. The raw score is the sum of responses and is converted to a T-score that has a population mean score of 50 with a standard deviation of 10; higher scores indicate better QOL.

    7. Change in Quick Aphasia Battery (QAB) Score [Baseline, Month 6]

      Assessment of language function. Includes eight subtests, each of which comprise sets of items that probe different language domains, vary in difficulty, and are scored with a graded system to maximize the informativeness of each item. The total scores range from 0 to 10, where: 0.00-4.99 = Severe Aphasia 5.00-7.49 = Moderate Aphasia 7.50-8.89 = Mild Aphasia 8.90-10.00 = No Aphasia

    8. Change in Boston Naming Test (BNT)-Short form Score [Baseline, Month 6]

      Measures confrontational word retrieval in individuals with aphasia or other language disturbance. Consists of 15 line-drawn pictures presented in order of difficulty from "easiest" (e.g., "house") to "most difficult" (e.g., "palette"). Participants have 20 seconds to name each item correctly with a cueing hierarchy. The total score is the sum of correct responses and ranges from 0 to 15; higher scores indicate greater confrontational word retrieval abilities.

    9. Change in Controlled Oral Word Association Test (COWAT) Score [Baseline, Month 6]

      The COWAT is verbal fluency test that measures spontaneous production of words belonging to the same category or beginning with some designated letter. The participants' task is to produce as many words as possible that begin with the given letter (F, A, or S) within a 1-minute time period. The total score is the total number of acceptable words produced for all three letters. Higher scores indicate greater verbal fluency.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    45 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Primary progressive aphasia diagnosis (logopenic or semantic variant)

    2. Peabody Picture Vocabulary Test (PPVT) score < -1.0 SD, serving as a literacy proxy for premorbid cognitive ability and ensuring English language fluency sufficient for participation in the study procedures.

    3. WAIS-IV Matrix Reasoning T score < 20, serving as an index of current general cognitive functioning to exclude those with severe cognitive impairment

    4. Stable and continuous access to internet service, email (WiFi "hotspot" to be provided if needed)

    5. Fluent in English language (due to outcomes validated in English versions only)

    Exclusion Criteria:
    1. Disorder other than PPA known to cause language dysfunction

    2. Diagnosis of nonfluent/agrammatic subtype of primary progressive aphasia

    3. History of traumatic brain injury

    4. Uncontrolled seizure disorder and/or recent (<5 years) history of seizure

    5. Metal implants in the head or neck

    6. Any skin disorder or skin sensitive area near stimulation locations

    7. Pregnant or breastfeeding

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 NYU Langone Health New York New York United States 10017

    Sponsors and Collaborators

    • NYU Langone Health

    Investigators

    • Principal Investigator: Leigh Charvet, PhD, NYU Langone Health

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    NYU Langone Health
    ClinicalTrials.gov Identifier:
    NCT05615922
    Other Study ID Numbers:
    • 22-01155
    First Posted:
    Nov 14, 2022
    Last Update Posted:
    Nov 14, 2022
    Last Verified:
    Nov 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Keywords provided by NYU Langone Health
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 14, 2022